VivoSeq
Dermatology

Hidradenitis Suppurativa (HS)

4

Pipeline Programs↗

8

Active Trials↗

4

Companies Involved↗

Hidradenitis Suppurativa (HS) is an early-stage landscape with 4 programs across 4 companies. The most active players are Incyte, Novartis, Harrison Dermatology. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

Phase 3Novartis logo

Novartis

1 program

ApprovedH

Harrison Dermatology

0 programs

PreclinicalJ

Julia Tatjana Maul

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Tibulizumab Dose a

Zura Bio Inc

Tibulizumab Dose B

Zura Bio Inc

Phase 31

Povorcitinib

Incyte

Approved1

Secukinumab

Novartis

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting5 · 63%
Not yet recruiting2 · 25%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

An Open-label, Multicenter Study Assessing Efficacy and Safety of Secukinumab up to One Year in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Recruiting·Novartis logoNovartis·Approved·NCT07489573·36 enrolled
An Open-label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Hidradenitis Suppurativa
Recruiting·BBeth Israel Deaconess Medical Center·Phase 2·NCT07263230·20 enrolled
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting·Incyte logoIncyte·Phase 3·NCT06855498·600 enrolled
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
Recruiting·Incyte logoIncyte·Phase 2·NCT07213973·40 enrolled
Global Healthcare Study on Hidradenitis Suppurativa
Recruiting·—·N/A·NCT07659769·9,600 enrolled
A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa
Active, not recruiting·ZZura Bio Inc·Phase 2·NCT06993610·225 enrolled
An Open-Label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Not yet recruiting·—·Phase 2·NCT07689188·10 enrolled
FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study
Not yet recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 1·NCT07668713·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)